Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2010 on January 27

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2010 on Thursday, January 27, 2011. During a conference call at 10:30 a.m. EST on January 27, company executives will review financial information and will address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by dialing 913-312-0732, confirmation code: 7584294. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 2:00 p.m. EST on January 27 through midnight EST on February 10, 2011. The replay will also be available through http://investor.bms.com or by dialing 402-280-9013, confirmation code: 7584294.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb Company
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Professional Services  Finance  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.